AEterna Zentaris Inc.’s Stock Is Buy After Today’s Huge Increase

 AEterna Zentaris Inc.'s Stock Is Buy After Today's Huge Increase

The stock of AEterna Zentaris Inc. (TSE:AEZ) is a huge mover today! About 39,441 shares traded hands. AEterna Zentaris Inc. (TSE:AEZ) has declined 1.12% since April 5, 2016 and is downtrending. It has underperformed by 5.91% the S&P500.
The move comes after 9 months positive chart setup for the $43.17 million company. It was reported on Nov, 9 by Barchart.com. We have $10.01 PT which if reached, will make TSE:AEZ worth $51.80M more.

Another recent and important AEterna Zentaris Inc. (TSE:AEZ) news was published by Businesswire.com which published an article titled: “Aeterna Zentaris Announces Closing of US$7560000 Registered Direct Offering of …” on November 01, 2016.

Aeterna Zentaris Inc. is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The company has a market cap of $43.17 million. The Firm operates through the biopharmaceutical segment. It currently has negative earnings. The Firm is engaged in drug development activities and in the promotion of products for others.

AEZ.TO Company Profile

Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Firm operates through the biopharmaceutical segment. The Firm is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Firm focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment